DarioHealth (NASDAQ:DRIO) Share Price Passes Below Two Hundred Day Moving Average - Here's What Happened

Key Points

• DarioHealth shares fell below their 200-day moving average, trading as low as $6.80 and last changing hands at $6.82, compared with the $7.74 average.
• Analyst sentiment is mixed: two analysts rate the stock a Buy, one rates it Hold and one Sell. The consensus rating is Hold, with an average price target of $10.00.
• DarioHealth reported a quarterly loss of $0.85 per share, better than the expected $1.22 loss, but revenue of $5.18 million came in below the $5.92 million forecast. The company remains unprofitable, with a negative net margin of 169.87%.

DarioHealth Corp. (NASDAQ:DRIO - Get Free Report)'s share price crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $7.74 and traded as low as $6.80. DarioHealth shares last traded at $6.82, with a volume of 6,322 shares changing hands.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on DRIO. TD Cowen lowered their price objective on shares of DarioHealth from $11.00 to $8.00 and set a "hold" rating for the company in a research note on Wednesday, August 12th. Alliance Global Partners assumed coverage on shares of DarioHealth in a research report on Wednesday, August 19th. They set a "buy" rating and a $12.00 target price on the stock. Weiss Ratings restated a "sell (e+)" rating on shares of DarioHealth in a report on Friday, July 10th. Finally, Stifel Nicolaus reaffirmed a "buy" rating and issued a $10.00 price target on shares of DarioHealth in a research report on Thursday, May 14th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $10.00.

DarioHealth Price Performance

The stock has a 50 day moving average of $7.20 and a 200-day moving average of $7.74. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.92 and a current ratio of 2.31. The company has a market cap of $66.84 million, a PE ratio of -1.11 and a beta of 1.12.

DarioHealth (NASDAQ:DRIO - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.85) EPS for the quarter, topping analysts' consensus estimates of ($1.22) by $0.37. DarioHealth had a negative net margin of 169.87% and a negative return on equity of 54.81%. The business had revenue of $5.18 million for the quarter, compared to analysts' expectations of $5.92 million. Equities analysts predict that DarioHealth Corp. will post -2.94 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Dennis Matheis acquired 14,430 shares of the company's stock in a transaction dated Thursday, July 23rd. The stock was acquired at an average cost of $6.93 per share, with a total value of $99,999.90. Following the completion of the purchase, the director owned 43,026 shares of the company's stock, valued at $298,170.18. This represents a 50.46% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 3.50% of the company's stock.

Hedge Funds Weigh In On DarioHealth

A number of institutional investors and hedge funds have recently modified their holdings of the company. Nantahala Capital Management LLC bought a new position in DarioHealth during the second quarter worth about $4,030,561. XTX Topco Ltd grew its stake in shares of DarioHealth by 229.0% in the 2nd quarter. XTX Topco Ltd now owns 62,511 shares of the company's stock valued at $42,000 after purchasing an additional 43,513 shares during the period. BlackRock Inc. bought a new stake in shares of DarioHealth in the 2nd quarter valued at approximately $249,000. Geode Capital Management LLC grew its stake in shares of DarioHealth by 167.9% in the 4th quarter. Geode Capital Management LLC now owns 49,567 shares of the company's stock valued at $564,000 after purchasing an additional 31,063 shares during the period. Finally, Kestra Advisory Services LLC acquired a new position in shares of DarioHealth in the 4th quarter worth approximately $35,000. Institutional investors and hedge funds own 33.39% of the company's stock.

About DarioHealth

DarioHealth NASDAQ: DRIO is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.